
Role of Genetic Testing in Management of Dyslipidemia
This website contains promotional content and is intended for Healthcare Professionals
This review describes the potential benefits of combination treatment and presents data supporting the use of single-pill combination (SPC) for increasing exposure to lipid-lowering treatment (LLT).
Highlights on the most recent real-world data on the use of PCSK9 inhibitors, including those from the Swedeheart and AIFA registries.
The synopsis of a Cochrane Systematic review on PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Why low-density lipoprotein-cholesterol, the only causal risk factor for atherosclerotic cardiovascular disease, is still overlooked and underestimated.